On November 20, 10x Genomics, Inc. falls 5.04% in Regular Trading, trading at $54.07 per share, with turnover of $13.39 million.
The move aligns with continued market digestion of ARK Invest's November 17 sale of 107,658 shares, as the rebound seen after that disclosure failed to hold.
Background developments show the company previously reported quarterly EPS of negative $0.15 and revenue of $150.667 million, both better than expectations, and raised full-year revenue guidance to $625 million-$635 million. However, several firms later cut target prices, and earlier CEO share sales of about 31,000 shares also continued to pressure near-term sentiment despite the stronger operating update.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments